A Novel Anti-CEACAM5 Monoclonal Antibody, CC4, Suppresses Colorectal Tumor Growth and Enhances NK Cells-Mediated Tumor Immunity
Figure 5
mAb CC4 enhanced the killing of HLA-Ilow colorectal cancer cells by CD16- NK cells.
CD56+CD16+ (A) and CD56+CD16- NK cells (B) isolated from human PBMCs were analyzed by flow cytometry. NK cytotoxicity assays were performed against various colorectal cancer cell lines using either CD56+CD16+ (C) or CD56+CD16- (D) NK cells as effector cells. Significant differences between mAb CC4 treatments and controls were indicated by double stars (**P<0.01).